News & Events

Kudos to Repare Therapeutics!

February 16, 2024

We commend Repare Therapeutics for their groundbreaking work on Camonsertib, an innovative step forward in cancer treatment. We’re proud to have contributed to this significant scientific effort, reflecting our dedication to advancing healthcare through fruitful collaborations. This achievement underscores the power of partnership in driving scientific breakthroughs. Kudos to our many scientists involved in this project.

Camonsertib‘s development represents a pivotal moment in targeted cancer therapy, focusing on ATR kinase—a crucial element in the DNA-damage response. This collaboration has led to a promising ATR inhibitor that demonstrates high potency and selectivity, offering new hope in treating genetically selected solid tumors.

We invite you to delve deeper into the scientific breakthroughs and the potential impact of Camonsertib by reading the full publication, showcasing the fruits of our partnership with Repare Therapeutics.

NuChem Sciences Tops the Quebec SME Ranking in Les Affaires Newspaper

November 24, 2023

NuChem Sciences is pleased to announce that it has achieved first place in the 2023 Quebec SME ranking, tied with other Quebec-based companies. The ranking by Les Affaires newspaper highlights NuChem Sciences’ undisputed leadership in pharmaceutical research.

2nd NuChem Symposium 2023

October 4th, 2023

On September 22, our headquarters on Cohen Street in Montreal was the scene of a mutually enriching encounter between academia and industry, thanks to the annual Symposium organized by NuChem Sciences.

A New Discovery

August 1st, 2023

NuChem is delighted to announce its acquisition by leading integrated drug discovery provider, Sygnature Discovery.
This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions and advances their vision to become the global market leader.

NuChem ranks 44th of the top 300 most important small and medium enterprises in Quebec

October 26, 2022

On the annual top 300 list produced by Les Affaires NuChem ranked in the top 50, and is the only Contract Research Organization (CRO) on the list, which is considered a benchmark for the entrepreneurial community.

NuChem awards for the 2nd time its industrial scholarship to two promising students

October 4, 2022

One year ago, the first industrial scholarship was awarded to three students in their final year of doctoral studies. NuChem Sciences has reiterated its commitment to the training of future scientific researchers in university by awarding this scholarship for the second time.

September 16: OmegaChem to host its first Omega Symposium

August 9, 2022

As a major employer of world-class scientific talent in the Quebec City area, OmegaChem is proud to host the first-ever Omega Symposium!

NuChem Sciences inaugurates its new laboratories and receives the Medal of the National Assembly of Quebec

July 14, 2022

NuChem’s leaders, scientists and support staff joined some 60 guests to inaugurate the world-class laboratories in Dobrin Street, Montreal.

NuChem Sciences: 10 years of accelerating drug discovery. Together.

June 20, 2022

As we celebrate the 10th anniversary of NuChem Sciences, here are the highlights of our company’s past achievements and its vision for an even brighter future.

NuChem Sciences awards scholarships to three promising students in Canadian universities

September 23, 2021

NuChem Sciences is pleased to announce a new fellowship to support and mentor three outstanding doctoral graduate students in the fields of organic synthesis or medicinal chemistry.

NuChem Sciences joins forces with OmegaChem to become Canada’s CRO focused on chemistry

September 3, 2021

We are pleased to announce that NuChem Sciences is joining forces with OmegaChem to become Canada’s CRO focused on chemistry.

Minister of labour J. Boulet visits Nuchem Sciences

August 8, 2021

We had the pleasure of hosting a visit of Mr. Jean Boulet, the Minister of Labour, Employment and Social Solidarity and Minister responsible for the Mauricie region, in our state-of-the-art laboratories to discuss with members of our teams.

NuChem Sciences announces new Discovery Partner Program™

April 15, 2021

This new service offers our team’s superior talent and our cutting-edge scientific technology, paired with responsive communication, efficiency and clarity along the drug discovery journey.

NuChem Sciences launches new brand and announces new name

April 15, 2021

After experiencing exponential growth in recent years, NuChem Therapeutics is proud to launch its new brand identity. As part of this exciting step forward, we will adopt a new corporate name: NuChem Sciences.

Universite de Montreal Journee Carriere

January 15, 2020

Our team was happy to meet and greet students at the Universite de Montreal MIL Campus as part of the Journee Carriere event.

NuChem Therapeutics Completed the Acquisition of Amplia Pharmatek

October 19, 2019

Amplia Pharmatek is an innovative service provider who specializes in Discovery Biology, in vivo Pharmacology, Pharmacokinetics and Toxicology.

Completion of a Successful Management Buyout Transaction At NuChem Therapeutics

February 22, 2019

On December 13th 2018, senior management of the company, comprised of Marc LeBel, Daniel Guay, Marc Janes and John Mancuso, acquired 95% of the voting shares from Amorchem LP, the venture capital fund which founded NuChem in 2011.